Nifty
:
24631.30
Sensex
:
80597.66
11.95 (0.05%)
57.75 (0.07%)
Nifty
Sensex
:
:
24631.30
80597.66
11.95 (0.05%)
57.75 (0.07%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
55/99

BSE: 532523 | NSE: BIOCON

NSE BSE
359.25
14-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  361
  •  368
  •  358.15
  •  360.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2525023
  •  914304593.15
  •  406
  •  291

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 48,043.79
  • 124.79
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 61,679.09
  • 0.14%
  • 1.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.45%
  • 1.48%
  • 12.58%
  • FII
  • DII
  • Others
  • 6.04%
  • 22.03%
  • 3.42%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.38
  • 16.40
  • 10.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.74
  • 18.31
  • 7.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.72
  • 4.33
  • 29.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 58.54
  • 61.59
  • 49.29

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.61
  • 3.78
  • 2.24

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.48
  • 18.06
  • 13.24

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
8.55
8.46
6.37
11.76
P/E Ratio
42.02
42.46
56.40
30.55
Revenue
14756
15262
17551
20633
EBITDA
3215
4227
3887
4901
Net Income
1023
1013
764
1411
ROA
1.9
1.8
1.2
2.1
P/B Ratio
3.95
1.99
1.96
1.85
ROE
5.43
4.89
3.59
6.1
FCFF
571
1408
1525
2315
FCFF Yield
0.95
2.35
2.54
3.86
Net Debt
13702
13795
8342
7185
BVPS
90.89
180.28
183.36
193.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
3,941.90
3,432.90
14.83%
4,417.00
3,917.10
12.76%
3,821.40
3,953.70
-3.35%
3,590.40
3,462.30
3.70%
Expenses
3,193.00
2,812.50
13.53%
3,338.80
3,001.20
11.25%
3,069.60
3,026.90
1.41%
2,905.00
2,720.70
6.77%
EBITDA
748.90
620.40
20.71%
1,078.20
915.90
17.72%
751.80
926.80
-18.88%
685.40
741.60
-7.58%
EBIDTM
19.00%
18.07%
24.41%
23.38%
19.67%
23.44%
19.09%
21.42%
Other Income
79.70
1,134.50
-92.97%
36.90
48.60
-24.07%
34.80
565.50
-93.85%
32.50
157.90
-79.42%
Interest
276.70
236.00
17.25%
212.40
227.00
-6.43%
223.40
266.70
-16.24%
225.60
247.70
-8.92%
Depreciation
455.00
405.40
12.23%
436.30
407.00
7.20%
425.40
414.50
2.63%
419.90
389.30
7.86%
PBT
96.90
1,145.50
-91.54%
486.80
321.70
51.32%
155.90
832.30
-81.27%
98.40
238.50
-58.74%
Tax
7.70
283.70
-97.29%
27.40
96.10
-71.49%
74.80
54.90
36.25%
71.30
41.60
71.39%
PAT
89.20
861.80
-89.65%
459.40
225.60
103.63%
81.10
777.40
-89.57%
27.10
196.90
-86.24%
PATM
2.26%
25.10%
10.40%
5.76%
2.12%
19.66%
0.75%
5.69%
EPS
0.23
5.49
-95.81%
2.87
1.13
153.98%
0.21
5.50
-96.18%
-0.13
1.05
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
15,770.70
15,261.70
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
Net Sales Growth
6.80%
3.43%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
 
Cost Of Goods Sold
5,419.90
5,197.50
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
Gross Profit
10,350.80
10,064.20
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
GP Margin
65.63%
65.94%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
Total Expenditure
12,506.40
12,243.00
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
Power & Fuel Cost
-
377.90
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
% Of Sales
-
2.48%
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
Employee Cost
-
3,144.40
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
% Of Sales
-
20.60%
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
Manufacturing Exp.
-
1,655.90
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
% Of Sales
-
10.85%
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
General & Admin Exp.
-
948.10
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
% Of Sales
-
6.21%
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
Selling & Distn. Exp.
-
649.90
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
% Of Sales
-
4.26%
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
Miscellaneous Exp.
-
269.30
128.60
297.40
107.70
60.40
36.10
37.20
47.40
41.00
100.80
% Of Sales
-
1.76%
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
EBITDA
3,264.30
3,018.70
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
EBITDA Margin
20.70%
19.78%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
Other Income
183.90
1,355.80
967.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
Interest
938.10
897.40
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
Depreciation
1,736.60
1,687.00
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
PBT
838.00
1,790.10
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
Tax
181.20
457.20
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
Tax Rate
21.62%
24.23%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
PAT
656.80
1,013.30
1,022.50
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
PAT before Minority Interest
385.00
1,429.40
1,297.80
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
Minority Interest
-271.80
-416.10
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
PAT Margin
4.16%
6.64%
6.93%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
PAT Growth
-68.14%
-0.90%
120.99%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
 
EPS
4.91
7.58
7.65
3.46
4.85
6.13
5.81
6.76
2.63
4.46
3.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
21,644.00
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
Share Capital
600.30
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
Total Reserves
20,618.80
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
Non-Current Liabilities
16,493.30
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
Secured Loans
10,502.50
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
Unsecured Loans
1,902.90
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
Long Term Provisions
260.80
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
Current Liabilities
14,333.80
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
Trade Payables
6,548.70
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
Other Current Liabilities
3,965.70
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
Short Term Borrowings
3,454.70
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
Short Term Provisions
364.70
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
Total Liabilities
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
Net Block
31,963.30
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
Gross Block
40,804.30
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
Accumulated Depreciation
8,841.00
7,286.50
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
Non Current Assets
42,253.40
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
Capital Work in Progress
8,508.40
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
Non Current Investment
679.70
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
Long Term Loans & Adv.
870.80
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
Other Non Current Assets
231.20
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
Current Assets
16,286.20
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
Current Investments
447.30
315.60
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
Inventories
4,931.10
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
Sundry Debtors
5,487.90
6,230.60
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
Cash & Bank
4,120.20
2,258.70
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
Other Current Assets
1,299.70
334.40
334.10
660.20
1,006.40
809.20
678.60
428.00
419.90
300.70
Short Term Loans & Adv.
917.00
1,096.00
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
Net Current Assets
1,952.40
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
Total Assets
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
4,061.20
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
PBT
1,886.60
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
Adjustment
1,711.20
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
Changes in Working Capital
923.00
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
Cash after chg. in Working capital
4,520.80
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-459.60
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-234.10
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
Net Fixed Assets
-393.50
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
Net Investments
-2,064.10
-47.80
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
Others
2,223.50
-633.50
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
Cash from Financing Activity
-1,854.00
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
Net Cash Inflow / Outflow
1,973.10
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
Opening Cash & Equivalents
919.50
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
Closing Cash & Equivalent
2,923.80
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
176.73
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
ROA
2.50%
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
ROE
7.03%
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
ROCE
7.43%
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
Fixed Asset Turnover
0.39
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
Receivable days
139.43
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
Inventory Days
117.49
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
Payable days
450.17
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
71.28
Cash Conversion Cycle
-193.26
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
Total Debt/Equity
0.84
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
Interest Cover
3.10
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Biocon gets nod to enter into agreements with Pro-zeal Green Power Sixteen
    8th Aug 2025, 10:00 AM

    The Board of Directors of the company at its meeting held August 07, 2025, had considered and approved the same

    Read More
  • Biocon reports 90% fall in Q1 consolidated net profit
    8th Aug 2025, 09:27 AM

    The total consolidated income of the company decreased by 11.95% at Rs 4,021.60 crore for Q1FY26

    Read More
  • Biocon’s arm launches Nepexto in Australia
    23rd Jul 2025, 11:19 AM

    Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe

    Read More
  • Biocon’s arm gets USFDA’s nod for Kirsty
    16th Jul 2025, 10:22 AM

    KIRSTY will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use

    Read More
  • Biocon’s arm receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
    7th Jul 2025, 09:50 AM

    Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product

    Read More
  • Biocon’s arm receives marketing authorisation for Vevzuo and Evfraxy in EU
    3rd Jul 2025, 11:10 AM

    Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product

    Read More
  • Biocon’s arm expands insulin access in Malaysia
    30th Jun 2025, 09:39 AM

    This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country

    Read More
  • Biocon’s arm receives NOC from Health Canada for Yesafili
    27th Jun 2025, 10:42 AM

    This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025

    Read More
  • Biocon’s arm partners with National Cancer Society of Malaysia
    24th Jun 2025, 10:36 AM

    This collaboration combines the company’s expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia

    Read More
  • Biocon to raise up to Rs 4,500 crore via QIP
    17th Jun 2025, 11:08 AM

    The Fund Raising Committee of the company at its meeting held on June 16, 2025 authorised the opening of the issue

    Read More
  • Biocon gets approval for diabetes drug Liraglutide in India
    3rd Jun 2025, 12:22 PM

    The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

    Read More
  • Biocon’s arm receives MHRA, UK approval for YESINTEK, Biosimilar Ustekinumab
    26th May 2025, 09:59 AM

    Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.